Lataa...
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2–4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this l...
Tallennettuna:
| Julkaisussa: | Drug Des Devel Ther |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5373840/ https://ncbi.nlm.nih.gov/pubmed/28392676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S108872 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|